“…86 Subsequently the SF-36 has been validated in patients with numerous diseases, including benign prostatic hypertrophy, 6,7 cancer, 1 clinical depression, 77 congestive heart failure, 77 coronary artery disease, 27 type 2 diabetes, 77 end-stage renal disease, 48 hypertension, 77 inflam- 77 and systemic lupus erythematosis. 78,[81][82][83] Additionally, the survey validated in patients with neurological and neurosurgical problems, including migraine headache, 1 stroke, 5 traumatic brain injury, 30 cervical spondylotic myelopathy, 51 low-back pain, 39 sciatica, 69 lumbar disc herniation, 32 and lumbar canal stenosis. 43 The present study adds IPSTs to the list of diseases for which the SF-36 provides valid data.…”